In multivariable models, the associations of elevated PTH (HR 1.50, 95%CI: 1.13, 1.99) and FGF-23 (HR 1.37, 95%CI: 1.07, 1.75) with incident HF were statistically significant.
Reassuming PTH serum concentration in contrary to 25(OH)D, P and Ca<sup>2+</sup> are significantly raised among the patients with HF and shows significant relationship with the clinical status expressed by the NYHA class.
In this pre-specified secondary analysis of a randomized controlled trial, we assessed in 158 male HF patients (vitamin D group: n = 80; placebo group: n = 78) between-group differences in calciotropic hormones (25OHD, 1,25-dihydroxyvitamin D [1,25(OH)<sub>2</sub>D], intact parathyroid hormone [iPTH]), and BTMs (cross-linked C-telopeptide of type I collagen, bone-specific alkaline phosphatase, undercarboxylated osteocalcin).
There were significant interactions between PTH and BP arm for both the cardiovascular (<i>P</i>-interaction=0.01) and heart failure (<i>P</i>-interaction=0.004) end points.
PTH is significantly elevated in non-ischaemic HF patients compared to non-HF volunteers and correlates with established factors of worse prognosis, including age, estimated glomerular filtration rate (eGFR), aspartate aminotransferase (AST), serum concentrations of creatinine, and NT-proBNP.
The objective of this study was to determine if vitamin D3 at a comparatively high dose would replete 25-hydroxyvitamin D (25(OH)D) stores, improve BNP, PTH, cardiopulmonary function, reduce inflammatory markers, and improve quality of life (QOL) in HF patients.
Cross sectional studies demonstrated that prevalence of HF is increased in patients with Vitamin D deficiency or parathyroid hormone (PTH) plasma level increase, whereas longitudinal studies showed enhanced risk of developing new HF in patients with Vitamin D deficiency.
Both HF and HTx participants had higher levels of bone resorption marker C-terminal telopeptide and parathyroid hormone with subjects in the HF group having the highest serum levels of all groups (<i>P</i> ≤ 0.05).